Early Detection of NSCLC Using Stromal Markers in Peripheral Blood
Technical Report,01 Sep 2015,31 Aug 2016
Weill Cornell Medical College New York United States
Pagination or Media Count:
A recent screening trial showed that the use of low dose computed tomography LDCT resulted in a 20 reduction in lung cancer mortality, however there was a 96 false positive rate associated with LDCT. Thus, there is an immediate clinical need to develop a diagnostic biomarker that would select patients with CT detected nodules for further testing. The ease with which blood can be sampled makes it a logical choice in which to discover diagnostic biomarkers, however the clinical utility of tumor derived proteins, miRNA or circulating tumor cells as blood-based biomarkers has been limited. In this proposal, instead of tumor-derived biomarkers, we will focus on host response to tumor growth. It has been well documented that tumor growth systemically stimulates and mobilizes BM-derived hematopoietic cells to the tumor bed to establish a permissive microenvironment. Preliminary studies in our lab have shown that in lung cancer patients, the circulating myeloid cells are transcriptionally altered and the alteration is tumor dependent.
- Medicine and Medical Research
- Genetic Engineering and Molecular Biology